Information for Patients and Physicians
Brentuximab vedotin (SGN-35) is an antibody-drug conjugate (ADC) comprising an anti-CD30 antibody linked to a potent, synthetic drug payload, monomethyl auristatin E (MMAE), using Seattle Genetics’ proprietary technology. The ADC is designed to be stable in the bloodstream, but to release MMAE, an antitubulin, upon internalization into CD30-expressing tumor cells, resulting in a targeted cell-killing effect. The CD30 antigen is an attractive target for cancer therapy because it is expressed on Hodgkin lymphoma, several types of T-cell lymphoma and other hematologic malignancies, but has limited expression on normal tissues.
Seattle Genetics is developing brentuximab vedotin in collaboration with Millennium: The Takeda Oncology Company under which Seattle Genetics has full commercialization rights to brentuximab vedotin in the United States and Canada, while Millennium has rights to commercialize the product candidate in the rest of the world.
For more detailed information about the clinical trials summarized below, click on the link to the trial listing at www.clinicaltrials.gov.